Indaptus Therapeutics, Inc. Accrued Liabilities, Current
Indaptus Therapeutics, Inc. (INDP) had Accrued Liabilities, Current of $3.07 million as of 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2021-08-16
- 2021-06-30: Accrued Liabilities, Current $3.07M.
- 2020-12-31: Accrued Liabilities, Current $2.86M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2021-06-30 | $3.07M 10-Q · filed 2021-08-16 |
| 2020-12-31 | $2.86M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |